Summary:
- This article discusses the development of a new subcutaneous autoinjector for the Alzheimer's disease drug Leqembi (lecanemab).
- Leqembi is a monoclonal antibody that has shown promising results in clinical trials for treating early-stage Alzheimer's disease by targeting amyloid-beta, a key protein involved in the disease.
- The new autoinjector is designed to make it easier for patients to self-administer the medication at home, which could improve accessibility and convenience for those living with Alzheimer's.